

Antibacterial photodynamic therapy on *staphylococcus aureus* and *pseudomonas aeruginosa in-vitro*

PS Thakuri, R Joshi, S Basnet, S Pandey, SD Taujale, N Mishra

Corresponding author: Pradip Shahi Thakuri, B.E., College of biomedical engineering and applied sciences, Dhana Ganesh-854 Hadigaun Margh, Hadigaun, Kathmandu, Nepal G.P box: 12521, Kathmandu, Nepal; e-mail: pthakuri13@gmail.com

ABSTRACT

Photodynamic therapy (PDT) involves the use of drugs or dyes known as photosensitizers, and light source which induces cell death by the production of cytotoxic reactive oxygen species (ROS). This principle of cell death can be utilized to kill bacteria *in vitro*. We propose the use of blue light emitting diodes (LEDs) and Riboflavin as the light source and photosensitizer for *in vitro* killing of *Staphylococcus aureus* and *Pseudomonas aeruginosa*. Circularly arranged 65-blue LED array was designed as the light source to fit exactly over 7cm culture plate. Riboflavin having non-toxic properties and nucleic acid specificity was used as a photosensitizer. Clinical isolates of *Staphylococcus aureus* and *Pseudomonas aeruginosa* were used in our study. Effect of PDT on viability on these species of bacteria was compared with control samples that included: control untreated, control treated with light only and control treated with riboflavin only. Statistical analysis was done using one-way ANOVA test. PDT against *Pseudomonas aeruginosa* and *Staphylococcus aureus* was significantly ($p < 0.05$) effective compared to all control samples. Combination of blue LEDs and Riboflavin in PDT against these bacterial species has been successfully demonstrated *in-vitro*. Therefore, PDT has promising applications in the process of treating superficial wound infections.

Keywords: Photodynamic therapy, photosensitizers, reactive oxygen species *Staphylococcus aureus*, *Pseudomonas aeruginosa*.

INTRODUCTION

Photodynamic therapy (PDT) is a process which involves bacterial cell death by the use of light energy of appropriate wavelength and photosensitive drugs or dyes. During PDT, a photosensitizer is added to a bacterial sample, which absorbs light energy and causes production of reactive oxygen species (ROS) within or outside microbial cell, depending upon the distribution of PS and penetration of light energy. These ROSs cause bacterial cell death either by oxidative damage to cell membrane or to deoxy-ribonucleic acid (DNA).¹

Photosensitization of bacteria has shown to be independent of the antibiotic resistance spectrum, non-mutagenic or genotoxic.² There appears to be no induction of resistance to PDT even after multiple treatments.³ Further, microbial selectivity is observed with PDT which can be due to differences in pharmacokinetics of mammalian and bacterial cells.⁴ There is potential for the use of PDT in the treatment of dermatological conditions such as infected ulcers, infected burn wounds and skin diseases involving microorganisms. It has the advantage that it may be a cost effective therapeutic option for developing countries as many of the photosensitizer have a minimal cost compared to many of the newer systemic antimicrobials.⁵

For infections of superficial wounds or open surgical wounds, broadband light sources, broad arrays of LEDs

or defocused laser beams are considered suitable light source. In our study, blue light emitting diodes are used as a light source, which offers various advantages over other light sources (lasers, UV-lamp) like large output, less thermal destruction, easy fabrication, large area illumination and cost efficiency.⁶ Riboflavin, a drug and a food additive, is considered non-toxic and possesses the property of photostimulation. It's been used before as a photosensitizer in combination with UV-A light for decontamination of blood components like platelets, plasma, red cell etc. Its nucleic acid specificity along with its limited tendency towards indiscriminate oxidation makes it a better candidate as photosensitizer for our study.⁷⁻⁹ Moreover, it can be formulated as a solution to optimize its usefulness for particular application on topical wound infections.

Staphylococcus aureus and *Pseudomonas aeruginosa* have been selected due to their high prevalence in wound infections. These species of bacteria have caused higher rate of morbidity in patients due to the high antibiotic resistance pattern towards the traditional use of antibiotics. Therefore, antimicrobial PDT, which is independent towards the antibiotic resistance pattern of bacteria, could prove beneficial to treat the wound infection.

Our study is focused on *in-vitro* effectiveness of PDT by the use of blue LEDs and riboflavin to kill these bacterial species.




Fig. 1. Emission spectrum of 65-LED array that shows peak spectrum at 470.84nm. The intensity is an arbitrary value for the array of blue LEDs

MATERIALS AND METHODS

LED Circuit: Sixty blue LED (RL5-B5515) circular array was used as the light source to uniformly irradiate 7cm culture plate containing bacterial sample. The distance of irradiation was taken 1.5cm.

Bacterial isolates: Twenty clinical isolates of *Staphylococcus aureus* and *Pseudomonas aeruginosa* isolated from different clinical samples were obtained from Nepal Medical College Teaching Hospital (NMCTH) Microbiology Department. These isolates were sub-cultured in Nutrient Agar (NA), Mannitol Salt-base Agar (MSA), and Mackonkey Agar (MA). Confirmatory tests and Gram staining for both of these isolates were performed. Gram positive cocci in clusters observed under microscope, yellow fluorescence on MSA and Slide coagulase test (bound coagulase test) positive was used to confirm *Staphylococcus aureus* from other coagulase-negative staphylococci. Gram negative bacilli observed under microscope, green fluorescence on NA and MA and Oxidase test positive was used to confirm *Pseudomonas aeruginosa*.

Photosensitizer: Riboflavin 5 phosphate was used as photosensitizer. It was stored in 0- 4°C in dark for the

entire period of experimentation. Spectral analysis of Riboflavin was performed using UV-Visible spectrophotometer (UV-2450 SHIMADZU) to generate absorbance spectrum of Riboflavin at 2mcg concentration.

Antimicrobial Photodynamic therapy

on bacteria: The day before performing PDT, pure cultures were inoculated in 100ml Nutrient Broth and incubated (37°C, 24hrs) to allow complete growth in the liquid growth medium. The overnight incubated broth culture was centrifuged at 3000 rpm for 10 minutes. Supernatant Nutrient Broth was discarded leaving bacterial pellet at the bottom of the centrifuge tube. Phosphate Buffered Saline (PBS) was added to the tube and the bacterial pellet was washed by shaking it gently. The washed pellet was again centrifuged for 10 minutes at

3000rpm. The pellet thus formed was then diluted with PBS. The initial population density of the sample was maintained at 1.5×10^8 CFU/ml after comparing with 0.5 McFarland standard solution i.e. Absorbance_(630nm) = 0.5 (1.5×10^8 CFU/ml). Stock solution of riboflavin i.e. 20mg/dl was prepared by dissolving 2mg of riboflavin in 10ml of sterile double distilled water. For the experimentation, three different control samples were prepared which are




Fig. 2. Absorption spectrum of Riboflavin @ 2mcg. The curve shows peak spectrum at 446.50nm (1), 373.50nm (2), 266.50nm (3), 223nm (4) with absorbance 0.0602, 0.052, 0.159 and 0.135




Fig. 3. Result showing PDT on one of the samples of *Staphylococcus aureus*. The experiment was repeated three times and the result shows the mean of data taken at various time intervals. The bar shows the standard deviation from the mean

control untreated, control treated to light only and control treated to riboflavin only.

6ml bacterial sample (with initial population density 1.5×10^8 CFU/ml) was aseptically transferred in each of the four 7cm culture plates with properly labeled control samples and PDT treated sample. Stock riboflavin was

each sample was done in triplicate plates.

STATISTICAL ANALYSIS

The results obtained were expressed as means \pm standard deviation and were analyzed statistically using one way ANOVA test. Statistical difference were considered significant at $p < 0.05$. All the experiments were performed in triplicate and repeated three times. Statistical analysis was performed using 'Origin50' software.

RESULTS

The emission spectrum of the LED array showed the peak spectrum at 470.84nm (Fig 1). Similarly, the spectral analysis of riboflavin showed the peak spectrum at four different regions with major peaks in UV- regions and a peak in the violet (near to blue) region with wavelength 446.50nm (Fig 2).

PDT treated samples in both bacterial species showed significant decrease ($p < 0.05$) in the viability when compared to all other control samples. Effect of bacterial killing was more pronounced when time of irradiation was increased in both these bacterial species. Fig. 3 shows the result of experimentation on one of the samples of *staphylococcus aureus*. Experimentation on other nine




Fig. 4. Result showing PDT on one of the samples of *Pseudomonas aeruginosa*. The experiment was repeated three times and the result shows the mean of data taken at various time intervals. The bar shows the standard deviation from the mean

samples also showed the significant difference ($p < 0.05$) in killing compared to control samples. Fig. 4 shows the experimentation on one of the samples of *Pseudomonas aeruginosa*. Similarly, for rest of the nine samples of *Pseudomonas aeruginosa* a significant difference in killing ($p < 0.05$) have also been observed (graph not shown). However, to achieve the same rate of killing, *Pseudomonas aeruginosa* required longer irradiation time than *Staphylococcus aureus*.

DISCUSSION

The present study has successfully demonstrated the efficacy of blue LEDs and riboflavin in the *in-vitro* inactivation of *Staphylococcus aureus* and *Pseudomonas aeruginosa*. Various wavelengths of blue light have been successfully used in the inactivation of various range of bacterial pathogens both *in-vivo* and *in-vitro*. 405nm blue led array alone has been successfully used for the *in-vitro* inactivation of wide range of bacterial pathogens. This effect of bacterial inactivation by the use of 405nm blue light can be attributed with the presence of endogenous porphyrins in bacteria.¹⁰ 470nm blue LED alone has also been used to kill methicillin resistant *Staphylococcus aureus in-vitro* [18]. Similarly, PDT using 470 ± 20 nm blue led has been found successful in the *in-vivo* inactivation of *Pseudomonas aeruginosa*.¹¹

Riboflavin has already been used as photosensitizer in blood decontamination processes as well as in inactivation of bacterial and fungal isolates combined with UV-A light.¹² The cytotoxic effect of riboflavin by light induced photosensitization has been attributed with the production of singlet oxygen, superoxide ions and hydroxyl radicals.^{9,13} These cytotoxic reactive oxygen species are primarily involved in cellular death of bacteria, which is either caused due to damage to their DNA or the lysis of their cell wall.

A longer irradiation time was required to kill *Pseudomonas aeruginosa* than *Staphylococcus aureus*. This has been attributed with the complex cell-wall structure of gram-negative species compared to gram-positive ones with lesser photosensitizer and light penetrating the cell-wall structure.¹⁴

Thus, PDT using blue light emitting diodes and riboflavin has been shown to be effective in killing *Staphylococcus aureus* and *Pseudomonas aeruginosa*. Blue light having soft tissue penetration depth of 2-3mm can be used in treatment of superficial wound infections. Riboflavin can be administered topically on the site of infection and irradiation can be performed for varying time interval to achieve a desired result.

As the use of antibiotics is rendered virtually unsuccessful by the high antibiotic resistance pattern by these bacterial species, a new treatment modality like this can prove to be effective in treating wound infections. A further insight in PDT with *in-vivo* experiment is required to ensure the effectiveness of the antimicrobial PDT.

ACKNOWLEDGEMENTS

We would like to acknowledge the entire team of Microbiology department of Nepal Medical College Teaching Hospital for providing the bacterial samples, Mr. Rajkumar Karki of Lomus Pharmaceuticals for his cooperation in spectral analysis of riboflavin and Dr. Deepak Subedi for the spectral analysis of light emitting diodes.

REFERENCES

1. Daia T, Huang YY, Hamblin MR. Photodynamic therapy for localized infections-State of the art. *Photodiagnosis Photodynamic Therapy* 2009; 6: 170-88.
2. Pupp G, Westphal C. How to choose appropriate antibiotics for diabetic foot infection? 2007; 9:56-60.
3. Wardlaw JL, Sullivan TJ, Lux CN, Austin FW. Photodynamic therapy against common bacteria causing wound and skin infections. *Vet J* 2011.
4. Smith and Nephew. Inc. Infection and Inflammation. 2005; 1-6.
5. O'Riordan K, Akilov OE, Hasan T. The potential for photodynamic therapy in the treatment of localized infections. *Photodiagnosis Photodynamic Therapy* 2005; 2: 247-62.
6. Luksiene Z. New approach to inactivation of harmful and pathogenic microorganisms by photosensitization. *Food Technol Biotechnol* 2005; 43: 411-8.
7. Wainwright M, Baptista MS. The application of photosensitisers to tropical pathogens in the blood supply. *Photodiagnosis Photodynamic Therapy* 2011; 8: 240-8.
8. Bryant BJ, Klein HJ. Pathogen Inactivation the Definitive Safeguard for the Blood Supply. *Arch Pathol Lab Med* 2007; 131: 719-33.
9. Frank Corbin III. Pathogen Inactivation of Blood Components: Current Status and Introduction of an Approach Using Riboflavin as a Photosensitizer. *Int'l J Hematol* 2002; 76: 253-7.
10. Maclean M, MacGregor SJ, Anderson JG, Woolsey G. Inactivation of bacterial pathogens following exposures to light from a 405-Nanometer Light-Emitting Diode Array. *Amer Soc Microbiol* 2009: 1932-7.
11. Hashimoto MCE, Toffoli DJ, Prates RA, Courrol LC, Riberio MS. Photodynamic inactivation of antibiotic resistant strain of *Pseudomonas aeruginosa in vivo*. Proc. of SPIE 2009; 7380.
12. Martins SAR, Combs JC, Noguera G *et al*. Antimicrobial Efficacy of Riboflavin/UVA Combination (365 nm) In Vitro for Bacterial and Fungal Isolates: A Potential New Treatment for Infectious Keratitis. *Investigative Ophthalmol Visual Sci* 2008; 49: 3402-9.
13. Sato K, Taguchi H, Maeda T *et al*. The primary cytotoxicity in ultraviolet-A-Irradiated Riboflavin solution is derived from hydrogen peroxide. *J Invest Dermatol* 1995; 105: 608-12.
14. Hamblin MR, Hasan T. Photodynamic therapy: A new antimicrobial approach to infectious disease? *Photochem Photobiol Sci* 2004; 3: 436-50.